Objective: Determine the prevalence of metabolic abnormalities (MA) and estimate the 10-year riskforcardiovasculardisease(CVD)amongLatinAmericanHIV-infectedpatientsreceivinghighly active anti-retroviral therapy (HAART). Methods:A cohort study to evaluate MA and treatment practicestoreduceCVDhasbeenconductedinsevenLatinAmericancountries.AdultHIV-infected patientswithatleastonemonthofHAARTwereenrolled.Baselinedataarepresentedinthisanalysis.Results:Atotalof4,010patientswereenrolled.Meanage(SD)was41.9(10)years;mediandurationofHAARTwas35(IQR:10-51)months,44%receivedproteaseinhibitors.Theprevalenceof dyslipidemiaandmetabolicsyndromewas80.2%and20.2%,respectively.Theoverall10-yearriskof CVD,asmeasuredbytheFraminghamriskscore(FRF),was10.4(24.7).LongerexposuretoHAART wasdocumentedinpatientswithdyslipidemia,metabolicsyndromeandtype2diabetesmellitus. TheFRFscoreincreasedwithdurationofHAART.Malepatientshadmoredyslipidemia,highblood pressure,smokinghabitandhigher10-yearCVDthanfemales.Conclusions:Traditionalriskfactors forCVDareprevalentinthissettingleadingtointermediate10-yearriskofCVD.Modiicationof theseriskfactorsthrougheducationandinterventionprogramsareneededtoreduceCVD.
INTRODUCTION
Since the introduction of highly active antiretroviral therapy (HAART) in 1995, a signiicantdecreaseinmortalitywasobservedin HIV-infected patients coupled with a marked reduction in the incidence of opportunistic infections and certain kind of cancers.
1 While these achievements are clearly remarkable, long-termcomplicationsofHAARTweresoon recognized including dyslipidemia, changes in body composition, insulin resistance, and glucoseintolerance,mineralbonedisease,and lactic acidosis. 2, 3 These abnormalities may be associated with the use of certain anti-retrovirals such as stavudine, zidovudine and proteaseinhibitors,butaneteffectofHIVinfectioncannotberuled-out.Additionally,current evidencesuggeststhatpatientsonHAARTare at risk of developing cardiovascular disease (CVD), and recent studies reported a higher prevalence of traditional risk factors for CVD in HIV-infected patients than in non-infected controls, such as arterial hypertension, dyslipidemia, and diabetes mellitus. [3] [4] [5] [6] [7] [8] [9] These complicationsjeopardizethelong-termbeneitsof HAART,andmaketheoverallmanagementof HIV-infectedpatientsmorecomplexandmore costlyaswell.
The World Health Organization reported in2007that1.6millionpeoplelivedwithHIV in LatinAmerica; 100,000 new cases were diagnosed that year; 58,000 cases died, and approximately 300,000 cases received HAART. 10 Scaling-up HAART programs are being implementedintheregiontoadegreethatmany countries provide anti-retroviral therapy free ofchargetoalargeproportionofpatients.As morepatientsreceiveHAARTintheregion,it is expected that a similar trend in metabolic complications and cardiovascular events is likelytobeobserved.However,theprevalence ofmetaboliccomplicationsinthesepatientsis largelyunknownintheregion,andtheroutine evaluationofmetabolicparametersisvariably undertakenbothatregionalandnationallevels. Therefore,theimpactofHAARTonmetabolic abnormalitiesandCVDhasnotbeenelucidatEste é um artigo Open Access sob a licença de CC BY-NC-ND edinLatinAmerica.Wereportherepre-interventiondata onmetabolicparametersandriskfactorsforCVDinalarge cohortofLatinAmericanHIV-infectedpatientsonHAART participatinginastudydesignedtoevaluatemodalitiesto minimize CVD risk in the region. To our knowledge, this istheirstattempttocharacterizetheseproblemsinLatin America.Theresultsofourstudywillallowusnotonlyto betterunderstandthelong-termcomplicationsofHAART inLatinAmerica,butalsotodeveloplocalguidelinestotreat andpreventCVD.
METHODS

Study design
The RAPID II study (Registry and Prospective Analysis ofPatientsInfectedwithHIVandDyslipidemia)isacohort web-based study designed to prospectively collect dataondemographic,metabolicandtreatmentmodalitiesamongHIV-infectedpatientsreceivingHAARTfrom LatinAmerica.
Setting
SevenLatinAmericancountries,eachonecontributingwith varyingnumberofparticipatingcentersfromArgentina(16 centersdistributedinBuenosAires,LaPlataandRosario), Brazil(15centersdistributedinSãoPaulo,RiodeJaneiro, Campinas,andPortoAlegre),Chile(twocentersinthecapital Santiago), Colombia (3 centers located in Bogotá and Cali),Ecuador(11centersdistributedinQuito,Cuencaand Guayaquil),Peru(ivecentersinthecapitalLima)andVenezuela(ninecentersdistributedinCaracas,Valencia,BarquisimetoandSanCristobal)participatedinthestudy. 
Study population
Outcomes
Themainoutcomesofthestudywerethedeterminationof metabolicriskfactorsatenrollmentandateverysixmonth offollow-upforatotaloftwo-years,theevaluationofcardiovascular events on every follow-up visit, and the lipid loweringbehaviorsoftheparticipatinginvestigatorsatenrollmentandsubsequentlyforatotaloftwo-years. Thefollowingriskfactorswereevaluatedincludingolder age(age≥45yearsformenand≥55yearsforwomen),currentcigarettesmoking,highbloodpressure(systolicblood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg and/or usage of an antihypertensive drug), low HDL-cholesterol(manwith≤40mg/dLorwomanwith≤ 50mg/dL),highLDL-cholesterol(fastingLDLlevels≥130 mg/dL), dyslipidemia (fasting serum triglycerides ≥ 150 mg/dLand/orfastingtotalserumcholesterol≥240mg/dL and/orlowHDL-cholesteroland/orhighLDL-cholesterol), bloodlipidnormalization(fastingserumtriglycerides>150 mg/dLandfastingtotalserumcholesterol<240mg/dLand HDL-cholesterol > 40 mg/dL and LDL-cholesterol < 130 mg/dL),type2diabetes(fastingserumglucose≥126mg/dL intwomeasurementsatleastoneweekapartand/orusageof oralanti-diabeticdrugs),physicalinactivity(lackofexercisingdeinedasphysicalactivityforatleast30minutesthree times-a-week), family history of premature cardiovascular disease(presenceofcardiovasculardiseaseineitheramale irst-degreerelative<55yearsoldorafemaleirst-degree relative<65yearsold),obesity(bodymassindex>30kg/ m 2 ), established coronary heart disease (history of either acutemyocardialinfarction,orangina,orsuddendeath,or myocardial revascularization), cardiovascular event (coronaryheartdiseaseorstrokeortransientischemicattackor peripheralarterydiseaseoranycombinationoftheabove), cardiovascularrisk(absoluteten-year-riskofcardiacdeath ormyocardialinfarctionusingtheFraminghamriskfactor algorithm),highriskpatients(thosewithestablishedorpre-dictedten-year-cardiovascularrisk≥20%),abnormalwaist circumference (man waist perimeter ≥ 102 cm or woman waist perimeter ≥ 88 cm), metabolic syndrome following ATPIIIcriteria 11 (simultaneouspresenceofatleastthreeout of ive of the following: triglycerides ≥ 150 mg/dL, abnormalwaistcircumference,fastingbloodglucose≥110mg/dL, highbloodpressure,lowHDL-cholesterol),abnormalbody fatdistribution(fatlossfromthefaceorextremities,orcentralfatgainoramixedpattern).
The lipid lowering therapeutic behavior of the participatinginvestigatorsineachcenterwasevaluatedatenrollment and every six-month period for two years. The behaviors were classiied into four groups: group A corresponded to direct lipid treatment and HAART switching, group B corresponded to direct lipid treatment but noHAARTswitching,groupCcorrespondedtonodirect lipid treatment and no HAART switching, and group D corresponded to no direct lipid treatment and HAART switching.Theinvestigatorswererequestedtoexplainwhy theyhaveselectedaspeciicbehavior.
Sample size determination and statistical analysis
Assuming rates of serum lipid normalization range from 10%to20%andtworatiosofdyslipidemicandnon-dyslipidemicpatients(1:1and3:1),asamplesizeof4000indi-vidualswasestimatedtoprovideenoughpowertoconduct the analysis of blood lipid normalization of dyslipidemia following one the four lipid lowering behaviors. Categorical variables were contrasted with the chi-square test with continuity correction or with the Fisher´s exact test. Continuous variables were contrasted with the student´s t-test ortheMann-Whitneytest.Alltestsweretwosided,alevelof signiicancewaspre-deinedat<0.05.
Ethical considerations
The study was approved by local and national regulatory agenciesineachparticipatingcenter.Eachpatientsignedan informedconsentform.
RESULTS
A total of 4,010 patients were recruited, three countries contributedto70%ofthesample:Argentinaenrolled1,015 patients, Brazil enrolled 1,001 patients and Venezuela enrolled807patients.Theremainingpatientswereenrolledby Colombia(474patients),Peru(417patients),Ecuador(252 patients)andChile(44patients).
Demographic and anthropometric data
Meanage(SD)ofthewholepopulationwas41.9 (10) Males Females andcardiovascularriskwereobserved,withmalepatientsat higherriskthanfemales.Obesityandmetabolicsyndrome predominatedinfemales.Theseresultsareremarkableand stress the necessity of incorporating the evaluation, treatment and prevention of modiiable risk factors and metabolicderangementsinHIV-infectedpatientsunderHAART intoroutinepracticeintheregion. The10-yearriskofdevelopingCVDasmeasuredbythe Framinghamriskfactorscorewasintermediateinthiscohortofpatients,butwasnotevenlydistributed,itwaslowin threecountries(Ecuador,ColombiaandPeru,<10%)and intermediateintheremainingfour(Argentina,Brazil,Chile andVenezuela,10-20%).However,theoverallestimatedrisk ofCVDinthislargecohortofpatientswashigherthanthat reportedforHIV-infectedpatientsonHAARTfromdeveloped countries with similar age distribution of subjects. [12] [13] [14] [15] [16] These studies estimated the 10-year risk of CVD in the lowriskcategory(estimatedrisk<10%):7.0%among403 Italianpatients, 12 7.4%inanotherItalianstudywith1,243 subjects, 13 6.2% in 603 Spanish patients, 14 6% in 2,386 American subjects, 15 and 8.8% among 219 Norwegian patients. 16 Wedidnotincludeacontrolgroupfromthegeneral population in our study, but a comparison of our results with those published recently from a large cross-sectional studyconductedinsevenLatinAmericancountriesamong 11,550non-HIVinfectedsubjectsfoundsimilarresultsfor the10-yearriskofCVD,with83%ofthesepatientsinthe low risk category and approximately 10% in the high risk category. 17 WeusedtheFraminghamriskalgorithmtopredictCVDinHIV-infectedpatients,althoughitwasnotdesignedtopredicttheCVDriskinthispopulation.Itsutility toestimatetheriskhasbeenquestionedmorerecently,asit 18 Better equations are clearly needed to more accuratelypredicttheriskofCVDinHIV-infectedpatients. Although the Framingham risk factor may not accurately predicttheriskofCVDinHIV-infectedpatientsonHAART, compellingevidenceofanassociationbetweenHAARTand CVD comes from the largest cohort of HIV-infected patientsrecruitedfortheDataCollectiononAdverseEventsof anti-HIVdrugsstudy(DADstudy). 19 Theirstreportofthat studyin2003showedthatforanyyearofexposuretoanti-retroviralmedicationstherewasa26%increaseintherate ofacutemyocardialinfarction. 19 Amorerecentreportafter completing5yearsoffollow-upshowed32%increaseinthe riskofCVD,mainlyduetoproteaseinhibitorsexposure. 20 In agreementwiththeseindings,wealsoobservedthatlonger exposuretoHAARTinourcohortcorrelatedwithmorerisk forCVD,asmeasuredbytheFraminghamriskscore,aswell aswithhigherratesofdyslipidemia,type2diabetesmellitus, andmetabolicsyndrome.
The individual role of traditional risk factors on the risk of CVD has been evaluated recently, concluding that theycontributeinthesimilardirectioninHIVpositiveand negative individuals. 9 However, the prevalence of certain traditionalriskfactorssuchassmokinganddyslipidemiais higherinHIV-infectedindividualscomparedtothegeneral population,thelatterasadirectresultfromHIVinfection itselforduetotheexposuretoanti-retrovirals. 19, [21] [22] [23] Ofnote, theoverallprevalenceofdyslipidemia(80.2%)andarterial bloodhypertension(31.5%)inourpopulationwashigher comparedtothatreportedfromlargecohortstudiesinthe developed world (45.9% and 7.2%, respectively), 19, 20 and from non-HIV infected subjects in LatinAmerica (6-20% and 9-29%, respectively. 17 Current or past smoking habit inourstudywascomparabletothatreportedamongHIVinfected patients 23 and non-HIV infected patients in Latin America. 17 Ontheotherhand,theprevalenceoftype2diabe-tesmellitus(3.3%)wassimilartothatreportedelsewhere, 19 butlowerthanthatreportedinnon-HIVinfectedsubjects in LatinAmerica (4-8%). 17 The contribution of metabolic syndrome to the risk of CVD in HIV-infected patients on HAARThasbeenchallengedrecently,asitsdeinitionmay not have a good sensitivity for this population. 24 The predictionofCVDriskwithmetabolicsyndromeisnotmore accuratethantheconferredbyitscomponents.Theoverall prevalenceofmetabolicsyndromeinourcohortofHIV-infectedpatientswassimilarthanthatreportedelsewhere. [25] [26] [27] GenderdifferencesintheriskofCVDamongHIV-infectedpatientsonHAARThavebeenreported. 20, 28 Wefound a predominance of dyslipidemia, smoking habit, and high blood pressure among males, resulting in higher risk for CVD. In contrast, females presented more metabolic syndrome and obesity. Interestingly, obesity was more prevalentamongfemalesthanamongmalesinalargecohortof non-HIV-infected patients in Latin America. 17 Prevalence ratesofobesityrangedfrom16.8%inBuenosAiresto30.4% in Mexico City in that study. Data from our cohort seem tocorrespondwiththeglobalobesityepidemicthataffects bothsexes,butparticularlyfemaleLatinAmericansubjects.
The study has limitations that should be considered when interpreting our results. Firstly, we did not include controls from the general population. Comparison of certaintraditionalriskfactorsforCVD,suchassmokinghabit andobesityinthegeneralpopulationofLatinAmericawere comparabletothosefoundinourstudy,buttheprevalence ofdyslipidemiaandhighbloodpressureweremarkedlydifferent,whichmayexplaintheincreaseriskofCVDobserved inourpatients.ThepurposeofourstudywasnottocomparetheCVDriskinHIV-infectedpatientswiththatofthe general population, but to show the current status of the metabolicproileandCVDriskinHIV-infectedpatientson HAART.Secondly,ourconvenientsamplemaynotberepresentativeofthewholepopulationofHIV-infectedpatients on HAART in Latin America, but to our knowledge this studyrepresentstheirstattempttoelucidatetheCVDrisk among these patients in the region, and its results may be usedforcomparisonwithstudiesthatmightbeconducted inthefuture.Lastly,someriskfactorsuniquetoHIV-infected patients on HAART such as altered body composition, includinglypoatrophyandlypodistrophycouldnotbeevaluated in this cohort of patients. Some studies have found acorrelationbetweenbodycompositionandmetabolicderangementsthatwewerenotabletoascertaininthisstudy.
Insummary,theintermediate10-yearriskofCVDobservedinthispopulationresultedfromthehighprevalence oftraditionalriskfactorsforCVD,andpointsoutthenecessityofimplementingprogramstoreduceit.Intervention strategiesshouldfocusonsmokingcessation,dietarycounseling,increaseexercise,andtreatmentofarterialbloodhypertensionanddyslipidemia,togetherwithmodiicationof HAARTregimenswhenneeded.
